Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 10/20 | 0.48 |
| ▸ | FPR3 | P25089 | 6/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19563290 | 0.88 | FPR2 (0.47) | FPR2AAK1LMNAGAAMAPT | |
| SCHEMBL16748863 | 0.88 | FPR2 (0.47) | FPR2AAK1LMNAGAAMAPT | |
| SCHEMBL19547869 | 0.85 | FPR2 (0.47) | FPR2LMNAMAPTMEN1KMT2A | |
| SCHEMBL19563271 | 0.85 | FPR2 (0.45) | FPR2LMNAMAPTMEN1KMT2A | |
| SCHEMBL18089387 | 0.85 | FPR2 (0.45) | FPR2LMNAMAPTMEN1KMT2A | |
| SCHEMBL16748807 | 0.84 | FPR2 (0.44) | FPR2FPR3AAK1LMNAMAPT | |
| SCHEMBL18064435 | 0.84 | FPR2 (0.44) | FPR2FPR3AAK1LMNAMAPT | |
| SCHEMBL19563339 | 0.84 | FPR2 (0.46) | FPR2AAK1LMNAGAAMAPT | |
| SCHEMBL16748772 | 0.84 | FPR2 (0.46) | FPR2AAK1LMNAGAAMAPT | |
| SCHEMBL19547845 | 0.83 | FPR2 (0.49) | FPR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926264-B2 | Phenylcarbamate derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3071548-B1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015077451-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | FPR2, FPR1, FPR3 | FPR2 1/4885FPR3 3/4885AAK1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.